ArticleAllergy, asthma & immunology research2026
Impact of Allergen-Specific Subcutaneous Immunotherapy on 12-Month Health-Related Quality of Life in Children and Their Parental Caregivers.
Article in Allergy, asthma & immunology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06535087 (The Impact of Airway Allergic Diseases on the Health-related Quality of Life of Children and Their Parents), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Impact of Airway Allergic Diseases on the Health-related Quality of Life of Children and Their Parents (Caregivers): A Prospective Controlled Study
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeRespiratory allergies impair children's health-related quality of life (HRQoL) and increase caregiver burden. While allergen-specific subcutaneous immunotherapy (SCIT) is known to improve clinical outcomes, its short-term impact on HRQoL in children and their parental caregivers remains underexplored. We aimed to evaluate the 12-month impact of SCIT on HRQoL, identify the determinants of HRQoL, and assess the correlation between symptom improvements and HRQoL gains.
methodsThis prospective study enrolled children with allergic rhinitis and/or asthma receiving either SCIT or standard pharmacotherapy, alongside their parental caregivers. Validated generic and disease-specific HRQoL instruments were administered at baseline and the 12-month follow-up. HRQoL changes were analyzed using paired
resultsAfter 12 months, children in the SCIT group (n = 132) showed significantly greater improvements in HRQoL than those receiving standard pharmacotherapy (n = 120) (ESs: 0.52-1.34 vs. 0.21-1.05), particularly in the domains of "usual activities" and "pain/discomfort." Caregivers in the SCIT group also experienced greater improvements in HRQoL (ESs: 0.54-0.60 vs. 0.23-0.26), particularly in the domains of "exhaustion," "anxiety," and "day-to-day activities." Multivariable regression analysis identified significant factors influencing HRQoL for both children and caregivers, including coexisting allergic conditions, disease control status, SCIT, and caregiver burdens. Symptom improvements with SCIT showed moderate-to-strong correlations with HRQoL gains.
conclusionsOver a 12-month period, SCIT was associated with significantly greater improvements in HRQoL for children with respiratory allergies and their parental caregivers compared with standard pharmacotherapy. Generic HRQoL instruments demonstrated good sensitivity to short-term treatment-related changes, supporting their utility as complementary outcome measures in SCIT evaluation.
trial registrationClinicalTrials.gov Identifier: NCT06535087.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.